胰周淋巴系统概况及在胰腺癌治疗中的意义

doi:10.16139/j.1007-9610.2019.03.021

摘要/Abstract

中图分类号:

R735.9

傅宁稹, 王伟珅, 詹茜, 沈柏用. 胰周淋巴系统概况及在胰腺癌治疗中的意义[J]. 外科理论与实践, 2019, 24(03): 276-280.

[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin,2017,67(1):7-30.
[2] Shi S, Hua J, Liang C, et al.Proposed modification of the 8th Edition of the AJCC Staging System for pancreatic ductal adenocarcinoma[J]. Ann Surg,2019,269(5):944-950.
[3] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[4] Rahib L, Smith BD, Aizenberg R, et al.Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res,2014,74(11):2913-2921.
[5] Tol JA, Gouma DJ, Bassi C, et al.Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery(ISGPS)[J]. Surgery,2014,156(3):591-600.
[6] Jang JY, Kang JS, Han Y, et al.Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study[J]. J Hepatobi-liary Pancreat Sci,2017,24(7):426-433.
[7] Jang JY, Kang MJ, Heo JS, et al.A prospective rando-mized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer[J]. Ann Surg,2014,259(4):656-664.
[8] Borghi F, Gattolin A, Garbossa D, et al.Embryologic bases of extended radical resection in pancreatic cancer[J]. Arch Surg,1998,133(3):297-301.
[9] Jennings RE, Berry AA, Strutt JP, et al.Human pancreas development[J]. Development,2015,142(18):3126-3137.
[10] Cesmebasi A, Malefant J, Patel SD, et al.The surgical anatomy of the lymphatic system of the pancreas[J]. Clin Anat,2015,28(4):527-537.
[11] Kanda M, Fujii T, Nagai S, et al.Pattern of lymph node metastasis spread in pancreatic cancer[J]. Pancreas,2011, 40(6):951-955.
[12] Nagakawa T, Kobayashi H, Ueno K, et al.Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas[J]. Cancer,1994,73(4):1155-1162.
[13] Nagakawa T, Konishi I, Ueno K, et al.A clinical study on lymphatic flow in carcinoma of the pancreatic head area--peripancreatic regional lymph node grouping[J]. Hepatogastroenterology,1993,40(5):457-462.
[14] Hirono S, Tani M, Kawai M, et al.Identification of the lymphatic drainage pathways from the pancreatic head guided by indocyanine green fluorescence imaging during pancreaticoduodenectomy[J]. Dig Surg,2012,29(2):132-139.
[15] Roche CJ, Hughes ML, Garvey CJ, et al.CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas[J]. Am J Roentgenol,2003,180(2):475-480.
[16] Imai H, Doi R, Kanazawa H, et al. Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer[J]. Int J Clin Oncol,2010,15(3):294-300.
[17] Kumon RE, Pollack MJ, Faulx AL, et al., In vivo characterization of pancreatic and lymph node tissue by using EUS spectrum analysis: a validation study[J]. Gastrointest Endosc,2010,71(1):53-63.
[18] Kurita A, Kodama Y, Nakamoto Y, et al.Impact of EUS-FNA for preoperative para-aortic lymph node staging in patients with pancreatobiliary cancer[J]. Gastrointest Endosc,2016,84(3):467-475 e1.
[19] Kalogeraki A, Papadakis GZ, Tamiolakis D, et al.EUS-fine-needle aspiration biopsy(FNAB) in the diagnosis of pancreatic adenocarcinoma: a review[J]. Rom J Intern Med,2016,54(1):24-30.
[20] Nathanson SD, Shah R, Rosso K.Sentinel lymph node metastases in cancer: causes, detection and their role in disease progression[J]. Semin Cell Dev Biol,2015,38:106-116.
[21] John BJ, Naik P, Ironside A, et al.Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival[J]. HPB (Oxford),2013,15(9):674-680.
[22] Aoyama T, Yamamoto N, Kamiya M, et al.The lymph node ratio is an independent prognostic factor in pancrea-tic cancer patients who receive curative resection followed by adjuvant chemotherapy[J]. Anticancer Res,2018,38(8):4877-4882.
[23] Yamada S, Fujii T, Hirakawa A, et al.Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer[J]. Langenbecks Arch Surg,2016,401(8):1143-1152.
[24] Chen JW, Bhandari M, Astill DS, et al.Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion[J]. HPB (Oxford),2010,12(2):101-108.
[25] Marmor S, Burke EE, Portschy PR, et al.Lymph node evaluation for treatment of adenocarcinoma of the pancreas[J]. Surg Oncol,2015,24(3):284-291.
[26] Kat’uchová J, Bober J, Kat’uch V, et al.Significance of lymph node micrometastasis in pancreatic cancer patients[J]. Eur Surg Res,2012,48(1):10-15.
[27] Jiang Y, Du Z, Yang F, et al.FOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasis[J]. PLoS One,2014,9(9):e106741.
[28] Schwarz L, Lupinacci RM, Svrcek M, et al.Para-aortic lymph node sampling in pancreatic head adenocarcinoma[J]. Br J Surg,2014,101(5):530-538.
[29] Robinson SM, Rahman A, Haugk B, et al.Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma[J]. Eur J Surg Oncol,2012,38(4):333-339.
[30] Liu Z, Luo G, Guo M, et al.Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer[J]. Pancreatology,2015, 15(3):253-258.
[31] Konstantinidis IT, Deshpande V, Zheng H, et al.Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?[J]. J Gastrointest Surg,2010,14(2):261-267.
[32] Buc E, Couvelard A, Kwiatkowski F, et al.Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion?[J]. Eur J Surg Oncol,2014,40(11):1578-1585.
[33] Pai RK, Beck AH, Mitchem J, et al.Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease[J]. Am J Surg Pathol,2011,35(2):228-234.
[34] Wang Z, Wu J, Li G, et al.Lymphangiogenesis and biological behavior in pancreatic carcinoma and other pancreatic tumors[J]. Mol Med Rep,2012,5(4):959-963.
35] Von Marschall Z, Scholz A, Stacker SA, et al. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer[J]. Int J Oncol,2005,27(3):669-679.
[36] Zorgetto VA, Silveira GG, Oliveira-Costa JP, et al.The relationship between lymphatic vascular density and vascular endothelial growth factor A(VEGF-A) expression with clinical-pathological features and survival in pancrea-tic adenocarcinomas[J]. Diagn Pathol,2013,8:170.
[37] Sipos B, Kojima M, Tiemann K, et al.Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis[J]. J Pathol,2005,207(3):301-312.
[38] Schneider M, Buchler P, Giese N, et al.Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread[J]. Int J Oncol,2006,28(4):883-890.
[39] Feig C, Gopinathan A, Neesse A, et al.The pancreas cancer microenvironment[J]. Clin Cancer Res,2012,18(16):4266-4276.
[40] Olszewski WL, Stanczyk M, Gewartowska M, et al.Lack of functioning intratumoral lymphatics in colon and pancreas cancer tissue[J]. Lymphat Res Biol,2012,10(3):112-117.
[41] Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics[J]. Science,2002,296(5574):1883-1886.
[42] He Y, Rajantie I, Pajusola K, et al.Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels[J]. Cancer Res,2005,65(11):4739-4746.
[43] Padera TP, Kuo AH, Hoshida T, et al.Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib[J]. Mol Cancer Ther,2008,7(8):2272-2279.
[44] Hoshida T, Isaka N, Hagendoorn J, et al.Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing deli-very of cancer cells to lymph nodes: therapeutic implications[J]. Cancer Res,2006,66(16):8065-8075.
[45] Singh I, Swami R, Khan W, et al.Lymphatic system: a prospective area for advanced targeting of particulate drug carriers[J]. Expert Opin Drug Deliv,2014,11(2):211-229.
[46] Ali Khan A, Mudassir J, Mohtar N, et al.Advanced drug delivery to the lymphatic system: lipid-based nanoformulations[J]. Int J Nanomedicine,2013,8:2733-2744.
[47] Kaminskas LM, Ascher DB, McLeod VM, et al. PEGylation of interferon alpha2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases[J]. J Control Release,2013,168(2):200-208.
[48] Li X, Dong Q, Yan Z, et al.MPEG-DSPE polymeric micelle for translymphatic chemotherapy of lymph node metastasis[J]. Int J Pharm,2015,487(1-2):8-16.
[49] Dunne AA, Boerner HG, Kukula H, et al.Block copolymer carrier systems for translymphatic chemotherapy of lymph node metastases[J]. Anticancer Res,2007,27(6B):3935-3940.
[50] Yang F, Jin C, Yang D, et al.Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment[J]. Eur J Cancer,2011,47(12):1873-1882.

胰周淋巴系统概况及在胰腺癌治疗中的意义

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱颖, 汤玉茗, 黄佳, 章永平, 姚玮艳. 全反式维A酸可促进肿瘤相关诱导配体对多种胰腺癌细胞的凋亡作用[J]. 内科理论与实践, 2023, 18(03): 171-176.
[2]	杨蕊馨, 杜宇童, 燕然林, 朱正纲, 李琛, 于颖彦. 消化道肿瘤单细胞转录组测序研究中生物样本前处理改良的探索[J]. 诊断学理论与实践, 2022, 21(05): 567-574.
[3]	何敏, 刘颖斌. 可切除胰腺癌的判断标准与治疗及其争议[J]. 外科理论与实践, 2022, 27(01): 6-10.
[4]	吴莉莉, 许耀麟, 楼文晖. 放射治疗在胰腺癌治疗中的应用现状和展望[J]. 外科理论与实践, 2022, 27(01): 25-29.
[5]	王冲, 程石. 可切除胰腺癌术前减黄的共识与争议[J]. 外科理论与实践, 2022, 27(01): 30-33.
[6]	卫积书, 黄诗朦. 胰腺癌嗜神经侵袭与神经重塑的研究历史和治疗现状[J]. 外科理论与实践, 2022, 27(01): 42-45.
[7]	李晓丽, 李为光, 钱爱华, 曹国良. 胰腺癌血清微RNA-486-3p的异常表达及对细胞增殖、凋亡的影响[J]. 内科理论与实践, 2021, 16(02): 121-125.
[8]	罗丹阳, 高益鸣. 口腔菌群与胰腺癌的相关性研究进展[J]. 外科理论与实践, 2021, 26(01): 84-86.
[9]	丁方谜, 刘振东. 叉头盒蛋白D1激活细胞外信号调节激酶通路促进胰腺癌侵袭转移[J]. 外科理论与实践, 2020, 25(06): 486-492.
[10]	钱梨寒, 沈柏用. 局部进展期胰腺癌综合治疗的研究进展[J]. 外科理论与实践, 2020, 25(05): 442-446.
[11]	吴璟奕, 李国静, 费健. 以急性胰腺炎为首发表现的胰腺癌（附17例报告）[J]. 外科理论与实践, 2020, 25(04): 326-330.
[12]	孙文韬, 邓侠兴. 胰腺癌与乙型肝炎感染的研究进展[J]. 外科理论与实践, 2020, 25(02): 171-173.
[13]	张超, 王伟艺, 唐文皓. 自噬在胰腺癌及其治疗中作用的研究进展[J]. 外科理论与实践, 2019, 24(06): 555-559.
[14]	薛美琳, 陈皓. 内镜超声检查及相关技术在胰腺癌诊治的应用[J]. 外科理论与实践, 2019, 24(06): 565-568.
[15]	严诚, 倪小艳, 姚秀忠, 陈财忠, 顾君英. 自由呼吸弥散加权磁共振成像在自身免疫性胰腺炎与胰腺癌诊断中的应用分析[J]. 外科理论与实践, 2019, 24(03): 230-235.